The genetic data services provider raised the cash from GSK as part of a collaboration deal, taking its total funding past $790m.

Pharmaceutical firm GlaxoSmithKline (GSK) has invested $300m in US-based DNA services provider 23andme as part of a four-year collaboration agreed by the companies yesterday. Founded in 2006, 23andme runs a service enabling users to send their genetic data to be tested in order to get information on their ancestry or risk of diseases such as…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.